Norbert Ndjeka

Norbert Ndjeka

Auto-generated profile, based on publicly available information

Norbert Ndjeka

Drug-Resistant TB, TB & HIV Directorate, National Department of Health, Pretoria, South Africa and University of KwaZulu-Natal

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
GGGabriela Beatriz Gomez
Gabriela Beatriz Gomez
MSMariana Siapka
Mariana Siapka
FCFrancesca Conradie
Francesca Conradie
NNNorbert Ndjeka
Norbert Ndjeka
AGAnna Marie Celina Garfin
Anna Marie Celina Garfin
AVAnna Vassall
Anna Vassall
Objectives Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in three epidemiological settings. Design Cost-effectiveness analysis using Markov cohort model. Setting South Africa, Georgia and the Philippines. Participants XDR-TB and multidrug-resistant tuberculosis (MDR-TB) failure and treatment intolerant patients. Interventions BPaL regimen. Primary and secondary outcome measures (1) Incremental cost per disability-adjusted life years averted by using BPaL against standard of care at the Global Drug Facility list price. (2) The potential maximum price at which the BPaL regimen could become cost neutral. Results BPaL for XDR-TB is likely to be cost saving in all study settings when pretomanid is priced at the Global Drug Facility list price. The magnitude of these savings depends on the prevalence of XDR-TB in the country and can amount, over 5 years, to approximately US$ 3 million in South Africa, US$ 200 000 and US$ 60 000 in Georgia and the Philippines, respectively. In South Africa, related future costs of antiretroviral treatment (ART) due to survival of more patients following treatment with BPaL reduced the magnitude of expected savings to approximately US$ 1 million. Overall, when BPaL is introduced to a wider population, including MDR-TB treatment failure and treatment intolerant, we observe increased savings and clinical benefits. The potential threshold price at which the probability of the introduction of BPaL becoming cost neutral begins to increase is higher in Georgia and the Philippines (US$ 3650 and US$ 3800, respectively) compared with South Africa (US$ 500) including ART costs. Conclusions Our results estimate that BPaL can be a cost-saving addition to the local TB programmes in varied programmatic settings.

17 November 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
LDLindy Dickson
Lindy Dickson
SRSacha Roxanne Le Roux
Sacha Roxanne Le Roux
LMLeila Mitrani
Leila Mitrani
JHJeremy Hill
Jeremy Hill
WJWaasila Jassat
Waasila Jassat
MNMark Nicol
Mark Nicol
Objectives Treatment for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is increasingly transitioning from hospital-centred to community-based care. A national policy for decentralised programmatic MDR/RR-TB care was adopted in South Africa in 2011. We explored variations in the implementation of care models in response to this change in policy, and the implications of these variations for people affected by MDR/RR-TB. Design A mixed methods study was done of patient movements between healthcare facilities, reconstructed from laboratory records. Facility visits and staff interviews were used to determine reasons for movements. Participants and setting People identified with MDR/RR-TB from 13 high-burden districts within South Africa. Outcome measures Geospatial movement patterns were used to identify organisational models. Reasons for patient movement and implications of different organisational models for people affected by MDR/RR-TB and the health system were determined. Results Among 191 participants, six dominant geospatial movement patterns were identified, which varied in average hospital stay (0–281 days), average patient distance travelled (12–198 km) and number of health facilities involved in care (1–5 facilities). More centralised models were associated with longer delays to treatment initiation and lengthy hospitalisation. Decentralised models facilitated family-centred care and were associated with reduced time to treatment and hospitalisation duration. Responsiveness to the needs of people affected by MDR/RR-TB and health system constraints was achieved through implementation of flexible models, or the implementation of multiple models in a district. Conclusions Understanding how models for organising care have evolved may assist policy implementers to tailor implementation to promote particular patterns of care organisation or encourage flexibility, based on patient needs and local health system resources. Our approach can contribute towards the development of a health systems typology for understanding how policy-driven models of service delivery are implemented in the context of variable resources.

8 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MDMurray Dryden
Murray Dryden
CMCaroline Mudara
Caroline Mudara
CVCaroline Vika
Caroline Vika
Lucille BlumbergLucille Blumberg
Lucille Blumberg
NMNatalie Mayet
Natalie Mayet
WJWaasila Jassat
Waasila Jassat
Background Post COVID-19 Condition (PCC) as defined by WHO refers to a wide range of new, returning, or ongoing health problems experienced by COVID-19 survivors, and represents a rapidly emerging public health priority. We aimed to establish how this developing condition has impacted patients in South Africa and which population groups are at risk. Methods In this prospective cohort study, participants ≥18 years who had been hospitalised with laboratory-confirmed SARS-CoV-2 infection during the second and third wave between December 2020 and August 2021 underwent telephonic follow-up assessment up at one-month and three-months after hospital discharge. Participants were assessed using a standardised questionnaire for the evaluation of symptoms, functional status, health-related quality of life and occupational status. Multivariable logistic regression models were used to determine factors associated with PCC. Findings In total, 1,873 of 2,413 (78%) enrolled hospitalised COVID-19 participants were followed up at three-months after hospital discharge. Participants had a median age of 52 years (IQR 41-62) and 960 (51.3%) were women. At three-months follow-up, 1,249 (66.7%) participants reported one or more persistent COVID-related symptom(s), compared to 1,978/2,413 (82.1%) at one-month post-hospital discharge. The most common symptoms reported were fatigue (50.3%), shortness of breath (23.4%), confusion or lack of concentration (17.5%), headaches (13.8%) and problems seeing/blurred vision (10.1%). On multivariable analysis, factors associated with new or persistent symptoms following acute COVID-19 were age ≥65 years [adjusted odds ratio (aOR) 1.62; 95%confidence interval (CI) 1.00-2.61]; female sex (aOR 2.00; 95% CI 1.51-2.65); mixed ethnicity (aOR 2.15; 95% CI 1.26-3.66) compared to black ethnicity; requiring supplemental oxygen during admission (aOR 1.44; 95% CI 1.06-1.97); ICU admission (aOR 1.87; 95% CI 1.36-2.57); pre-existing obesity (aOR 1.44; 95% CI 1.09-1.91); and the presence of ≥4 acute symptoms (aOR 1.94; 95% CI 1.19-3.15) compared to no symptoms at onset. Interpretation The majority of COVID-19 survivors in this cohort of previously hospitalised participants reported persistent symptoms at three-months from hospital discharge, as well as a significant impact of PCC on their functional and occupational status. The large burden of PCC symptoms identified in this study emphasises the need for a national health strategy. This should include the development of clinical guidelines and training of health care workers, in identifying, assessing and caring for patients affected by PCC, establishment of multidisciplinary national health services, and provision of information and support to people who suffer from PCC.

6 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KDKeertan Dheda
Keertan Dheda
SOSuzette Oelofse
Suzette Oelofse
AEAliasgar Esmail
Aliasgar Esmail
EPElize Pietersen
Elize Pietersen
SMStuart Meier
Stuart Meier
NNNorbert Ndjeka
Norbert Ndjeka
Background: Rifampicin-resistant tuberculosis (RR-TB) remains a threat to global TB control. The shorter (~6-month) all-oral bedaquiline-pretomanid-linezolid (BPaL) ± fluoroquinolone regimens have been endorsed by the WHO based on published trial data. However, programmatic data regarding its efficacy and safety remain limited.Methods: In this observational cohort study, we evaluated programmatic data from 8,736 RR-TB patients registered on the Electronic-Drug-Resistant-TB-Web-application (EDRWeb) between September 2022 and March 2025 across 5 high-burden South African provinces. We compared the ~6-month BPaL or BPaL with levofloxacin (BPaL/L) regimens with the superseded all-oral bedaquiline-linezolid-containing regimens (9–20-months). WHO-defined treatment-related outcomes were compared using regression models. Clinical characteristics and adverse events were compared descriptively, and time-to-event analyses were performed.Findings: 7504 (85·9%) eligible patients were included in the analysis. After adjusting for potential confounders (previous RR-TB, HIV, body-mass-index, haemoglobin and sputum smear positivity), BPaL/L were associated with significantly lower odds (95% CI) of unfavourable treatment outcomes [adjusted odds ratio (aOR) 0·46 (0·39 – 0·55); p<0·0001]. The proportion of unfavourable outcomes was lower with BPaL/L than with prior regimens [570/2965 (19·2%) vs 1543/4539 (34·0%); p<0·0001], driven primarily by fewer deaths [211/2965 (7·1%) vs 574/4539 (12·7%); p<0·0001] and less loss to follow-up [289/2965 (9·8%) vs 852/4539 (18·8%); p<0·0001]. Independent predictors of unfavourable outcome with BPaL/L were previous RR-TB, and moderate-to-severe anaemia (p<0·05). Fewer severe (Grade 3–5) adverse events were seen with BPaL/L [229/919 (24·9%) vs 528/1511 (34·9%); OR 0·62 (0·52 – 0·74); p<0·0001].Interpretation: In routine practice, 6-month BPaL/L regimens improved clinical outcomes and reduced severe toxicity compared to prior, longer all-oral regimens. However, one-in-five patients still experienced an unfavourable outcome, and treatment related adverse events remained common. These findings inform clinical management and underscore the need for more effective regimen development for DR-TB.Funding: SA Medical Research Council; European and Developing Countries Clinical Trials Partnership; National Research Foundation.

28 May 2026 in The Lancet Regional Health - Africa
Verified
Journal Article
Open access
NINazir Ahmed Ismail
Nazir Ahmed Ismail
MLMarguerite Massinga Loembé
Marguerite Massinga Loembé
NNNorbert Ndjeka
Norbert Ndjeka

1 November 2022 in medRxiv
Verified
Preprint
Open access
PDF file
WJWaasila Jassat
Waasila Jassat
CMCaroline Mudara
Caroline Mudara
CVCaroline Vika
Caroline Vika
RWRichard Welch
Richard Welch
TATracy Arendse
Tracy Arendse
CCCheryl Cohen
Cheryl Cohen
Background A third of people may experience persistent symptoms following COVID-19. With over 90% of South Africans having evidence of prior SARS-CoV-2 infection, it is likely that many people could be affected by Post COVID-19 Condition (PCC). Methods The was a prospective, longitudinal observational cohort study recruiting hospitalised and non-hospitalised participants, infected during the periods that Beta, Delta and Omicron BA.1 variants dominated in South Africa. Participants aged 18 years or older were randomly selected to undergo telephone assessment at 1, 3 and 6 months after hospital discharge or laboratory-confirmed SARS-CoV-2 infection. Participants were assessed using a standardised questionnaire for evaluation of symptoms and health-related quality of life. We used negative binomial regression models to determine factors associated with the presence of ≥1 symptoms at 6 months. Findings Among hospitalised and non-hospitalised participants, 46.7% (1,227/2,626) and 18.5% (199/1,074) had ≥1 symptoms at 6 months (p=<0.001). Among hospitalised participants 59.5%, 61.2% and 18.5% experienced ≥1 symptoms at 6 months among individuals infected during the Beta, Delta and Omicron dominant waves respectively. Among PLWH who were hospitalised, 40.4% had ≥1 symptoms at 6 months compared to 47.1% among HIV-uninfected participants (p=0.108). Risk factors for PCC included older age, female sex, non-black race, the presence of a comorbidity, greater number of acute COVID-19 symptoms, hospitalisation/ COVID-19 severity and wave period (individuals infected during the Omicron-dominated wave had a lower risk of persistent symptoms [adjusted Incident Risk Ratio 0.45; 95% Confidence Interval 0.36 – 0.57] compared to those infected during the Beta-dominated wave). There were no associations between self-reported vaccination status before or after SARS-CoV-2 infection with persistent symptoms. Interpretation The study revealed a high prevalence of persistent symptoms among South African participants at 6 months although decreased risk for PCC among participants infected during the Omicron BA.1 wave. These findings have serious implications for countries with resource-constrained healthcare systems. Funding Bill & Melinda Gates Foundation, UK Foreign, Commonwealth & Development Office, and Wellcome.